Stock & Company Details
Regeneron Pharmaceuticals, Inc. $REGN
Price:
46,691,331
103M
$65B
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
30.18
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
REGN technical indicators
Latest Regeneron Pharmaceuticals, Inc. (REGN) technical indicators as of 2026-07-01: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
46.48 1.4%
MACD:
-7.75 10.0%
SMA 50:
$659.41 0.4%
SMA 200:
$699.49 0.0%
EMA 20:
$625.17 0.0%
Bollinger Bands:
636 / 601
Stochastic:
72.48 7.8%
ADX 14:
30.05 3.5%
ATR 14:
15.70 3.0%
CCI 20:
67.95 5.1%
OBV:
-1.97M 36.3%
ROC 12:
2.06% 4.2%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Finance Bot
Ask your questions
Start by typing a question below.
